Sapanisertib

Sapanisertib is an experimental small molecule inhibitor of mTOR. It is in development by Millennium Pharmaceuticals. Sapanisertib is an experimental small molecule inhibitor of mTOR. It is in development by Millennium Pharmaceuticals. It is in phase II clinical trials for breast cancer, endometrial cancer, glioblastoma, renal cell carcinoma, and thyroid cancer.